Viking (VKTX.US) Plunges in Pre-market Trading! Mid-term trial results of the oral weight loss drug VK2735 are below expectations.

Wisdom Financial App learned that due to lower-than-expected mid-term trial data for Viking Therapeutics' experimental oral weight-loss drug, as of the time of writing, the stock plummeted nearly 34% in pre-market trading on Tuesday. Viking said in a statement that its oral GLP-1R/GIPR dual agonist VK2735 can help patients lose up to 12.2% of their body weight. However, about 28% of patients dropped out of the trial in just three months. This has shaken people's confidence in the drug's ability to compete with medications from Eli Lilly and Company (LLY.US) and Novo Nordisk (NVO.US). Mizuho Securities analyst Jared Holz stated, "It is worth noting that the drop-out rate at 13 weeks was this high."